|本期目录/Table of Contents|

[1]杜庆安,丁蓉蓉,蔡 凯,等.HER-2多肽负载自体树突状细胞治疗HER-2阳性乳腺癌的初步研究[J].医学研究与战创伤救治(原医学研究生学报),2013,15(06):581-584.[doi:10.3969/j.issn.1672-271X.2013.06.009]
　DU Qing-an,DING Rong-rong,CAI Kai,et al.The primary effect of vaccination with autologous dendritic cells loaded with Her-2 peptides against Her-2 positive breast cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2013,15(06):581-584.[doi:10.3969/j.issn.1672-271X.2013.06.009]
点击复制

HER-2多肽负载自体树突状细胞治疗HER-2阳性乳腺癌的初步研究()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第15卷
期数:
2013年06期
页码:
581-584
栏目:
出版日期:
2013-11-20

文章信息/Info

Title:
The primary effect of vaccination with autologous dendritic cells loaded with Her-2 peptides against Her-2 positive breast cancer
作者:
杜庆安1; 丁蓉蓉2; 蔡 凯3; 江龙委3
210002 江苏南京，解放军81医院,1.烧伤整形科,2.门诊部,3.肿瘤生物治疗科
Author(s):
DU Qing-an1; DING Rong-rong2; CAI Kai3; JIANG Long-wei3.
1.Department of Burn and Plastic Surgery，2.Department of Outpatients Service，3.Department of Tumor Biological Therapy，81 Hospital of PLA，Nanjing，Jiangsu 210002，China
关键词:
乳腺癌; 树突状细胞; 多肽; 免疫治疗
Keywords:
breast cancer;  denedrtic cells;  peptides;  immunotherapy
分类号:
R737.9
DOI:
10.3969/j.issn.1672-271X.2013.06.009
文献标志码:
A
摘要:
目的 探讨HER-2多肽负载自体树突状细胞治疗HER-2阳性乳腺癌的安全性和有效性。方法 15例HER-2阳性及HLA-A2阳性的乳腺癌患者(Ⅱ～Ⅲ期)经标准治疗后行HER-2多肽负载自体树突状细胞治疗。检测治疗前后患者外周血淋巴细胞亚群、Th1型和Th2型细胞因子水平，以及IFN-γ分泌型CD8+T淋巴细胞比例，观察治疗相关毒副反应及近期临床疗效。结果 治疗后外周血CD3+比例、CD3+CD4+比例和CD4+/CD8+比值较治疗前明显升高(P<0.05)，治疗后血清中IL-2、TNF-α、IFN-γ较治疗前明显上升(P<0.05)，IL-4、IL-10、IL-12无明显变化(P＞0.05)，IL-10/TNF-α比值较治疗前显著下降(P<0.05)。IFN-γ分泌型CD8+T淋巴细胞比例较治疗前也显著上升(P<0.05)。在治疗结束后的随访时间内，15例患者取得了13例病情稳定，2例病情进展的近期临床疗效。所有治疗患者均未出现3～4级不良反应。结论 HER-2阳性乳腺癌行HER-2多肽负载自体树突状细胞治疗是安全可行的，可改善患者细胞免疫功能并提高Th1型细胞因子水平，促进特异性抗肿瘤细胞免疫应答并产生一定临床获益。
Abstract:
Objective To investigate the safety and efficacy of vaccination with autologous dendritic cells loaded with Her-2 peptides against Her-2 positive breast cancer after standard therapy.Methods Fifteen HLA-A2 positive and Her-2 positive breast cancer patients (stage Ⅱ and Ⅲ) after standard therapy were treated with autologous dendritic cell loaded with Her-2 HLA-A2-restricted peptides.The peripheral blood lymphocyte subsets,Th1 type cytokines (IL-2、IL-12、TNF-α、IFN-γ) and Th2 type cytokines (IL-4、IL-10) level in serum,and the blood IFN-γ+CD8+T ratio were examined.Results The percentage of CD3+ and CD3+CD4+ and ratio of CD4+/CD8+ increased significantly(P<0.05) after the vaccination.Serum levels of IL-2,TNF-α and IFN-γ increased significantly(P<0.05) after treatment,while serum levels of IL-4,IL-10,and IL-12 showed no obvious change(P>0.05).The IL-10/TNF-α ratio decreased significantly(P<0.05) after the vaccination.The IFN-γ+CD8+T cells also increased significantly(P<0.05) after the vaccination.No grade 3～4 adverse event happened in all cases during treatment.Conclusion Vaccination with autologous dendritic cells loaded with Her-2 peptides against Her-2 positive breast cancer after standard therapy is safe and feasible.This treatment could improve the body's cellular immune function and elicit Th1 immune responses.The increased tumor special cellular immune responses could produce clinical benefits to some degree.

参考文献/References:

[1]赵 平,孔灵芝.中国肿瘤死亡报告:全国第三次死因回顾抽样调查[M].北京:人民卫生出版社,2010:132-143.
[2]Siegel R,Naishadham D,Jemal A.Cancer statistics,2013[J].CA Cancer J Clin,2013,63(1):11-30.
[3]Tagliabue E,Balsari A,Campiglio M,et al.HER2 as a target for breast cancer therapy[J].Expert Opin Biol Ther,2010,10(5):711-724.
[4]Arteaga CL,Sliwkowski MX,Osborne CK,et al.Treatment of HER2-positive breast cancer:current status and future perspectives[J].Nat Rev Clin Oncol,2012,9(1):16-32.
[5]Palucka K,Ueno H,Banchereau J.Recent developments in cancer vaccines[J].J Immunol,2011,186(3):1325-1331.
[6]Copier J,Bodman-Smith M,Dalgleish A.Current status and future applications of cellular therapies for cancer[J].Immunotherapy,2011,3(4):507-516.
[7]孔练花，李 军，韩亚萍，等.基因修饰的树突状细胞体外免疫功能的初步研究[J].东南国防医药,2011,13(6):481-484.
[8]Eisenhauer EA,Therasse P,Bogaerts J,et al.New response evaluation criteria in solid tumours:revised RECIST guideline(version 1.1)[J].Eur J Cancer,2009,45(2):228-247.
[9]Trotti A,Colevas AD,Setser A,et al.CTCAE v3.0:development of a comprehensive grading system for the adverse effects of cancer treatment[J].Semin Radiat Oncol,2003,13(3):176-181.
[10]Eccles SA.The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology[J].Int J Dev Biol,2011,55(7-9):685-696.
[11]Disis ML,Wallace DR,Gooley TA,et al.Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer[J].J Clin Oncol,2009,27(28):4685-4692.
[12]Vergati M,Schlom J,Tsang KY.The consequence of immune suppressive cells in the use of therapeutic cancer vaccines and their importance in immune monitoring[J].J Biomed Biotechnol,2011,2011:182413.
[13]Wheeler CJ,Black KL,Liu G,et al.Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients[J].Cancer Res,2008,68(14):5955-5964.
[14]Braumuller H,Wieder T,Brenner E,et al.T-helper-1-cell cytokines drive cancer into senescence[J].Nature,2013,494(7437):361-365.
[15]Kirkwood JM,Lee S,Moschos SJ,et al.Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma:Eastern Cooperative Oncology Group Phase II Trial E1696[J].Clin Cancer Res,2009,15(4):1443-1451.

相似文献/References:

[1]邵明永,丁庆莉,高 纯,等.CA125和CA153联合检测对乳腺癌的诊治价值[J].医学研究与战创伤救治(原医学研究生学报),2013,15(05):433.[doi:10.3969/j.issn.1672-271X.2013.05.001]
　SHAO Ming-yong,DING Qing-li,GAO Chun,et al.Roles of detection of CA125 and CA153 in diagnosis and therapy of breast cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2013,15(06):433.[doi:10.3969/j.issn.1672-271X.2013.05.001]
[2]孔练花,李 军,韩亚萍,等.基因修饰的树突状细胞体外免疫功能的初步研究[J].医学研究与战创伤救治(原医学研究生学报),2011,13(06):481.
　KONG Lian-hua,LI Jun,HAN Ya-ping,et al.The preliminary study on the immune function of the gene modified dendritic cells in vitro[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2011,13(06):481.
[3]蒋 静,程珠玲.乳腺肿瘤患者心理护理的对策[J].医学研究与战创伤救治(原医学研究生学报),2011,13(06):553.
[4]朱成宾,潘玉琴,何帮顺.微小RNA多态性与中国女性人群乳腺癌发病及病理特征的相关性研究[J].医学研究与战创伤救治(原医学研究生学报),2015,17(01):22.[doi:10.3969/j.issn.1672-271X.2015.01.007]
　ZHU Cheng-bin,PAN Yu-qin,HE Bang-shun..Study on the association of polymorphisms in microRNAs and risk of breast cancer and its clinic pathological parameters[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(06):22.[doi:10.3969/j.issn.1672-271X.2015.01.007]
[5]刘 彧,童清平,连 娟,等.乳腺癌弹性超声特征与分子生物学指标的相关性研究[J].医学研究与战创伤救治(原医学研究生学报),2015,17(02):116.[doi:10.3969/j.issn.1672-271X.2015.02.002]
　LIU Yu,TONG Qing-ping,LIAN Juan,et al.Relationship between ultrasonic elastography features and ER， PR， Her-2 and Ki67 expression in molecular biology of breast[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(06):116.[doi:10.3969/j.issn.1672-271X.2015.02.002]
[6]苏寒,毛钊,陈伟,等.牙龈卟啉单胞菌脂多糖对树突状细胞成熟及功能影响的体外研究[J].医学研究与战创伤救治(原医学研究生学报),2017,19(05):465.[doi:10.3969/j.issn.1672-271X.2017.05.005]
　SU Han,MAO Zhao,CHEN Wei,et al.Effects of Porphyromonas gingivalis-lipopoly saccharide on the maturation and functions of dendritic cells[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2017,19(06):465.[doi:10.3969/j.issn.1672-271X.2017.05.005]
[7]陈涛,王璇,程凯,等.CD47在乳腺癌及癌旁组织中的表达及其意义[J].医学研究与战创伤救治(原医学研究生学报),2018,20(05):501.[doi:10.3969/j.issn.1672-271X.2018.05.012]
　CHEN Tao,WANG Xuan,CHENG Kai,et al.Expression and significance of CD47 in breast cancer and pericancerous tissues[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2018,20(06):501.[doi:10.3969/j.issn.1672-271X.2018.05.012]
[8]陈雨秋,周国华,顾军.半乳糖凝集素3与乳腺癌的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2020,22(5):510.[doi:10.3969/j.issn.1672-271X.2020.05.013]
　CHEN Yu-qiu,ZHOU Guo-hua,GU Jun.Research progress of galectin-3 and breast cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2020,22(06):510.[doi:10.3969/j.issn.1672-271X.2020.05.013]
[9]地里呼玛尔·吐鲁洪,李欣芳,王少华.HR+/HER2-乳腺癌内分泌治疗的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2021,23(04):387.[doi:10.3969/j.issn.1672-271X.2021.04.011]
　Dilihumaer Tuluhong,LI Xin-fang,WANG Shao-hua.The trend of endocrine therapeutic approach in HR+/HER2-breast cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(06):387.[doi:10.3969/j.issn.1672-271X.2021.04.011]
[10]何小芳,周敏,熊朝月,等.乳腺癌超声征象及其术后复发的危险因素分析[J].医学研究与战创伤救治(原医学研究生学报),2022,24(3):274.[doi:10.3969/j.issn.1672-271X.2022.03.011]
　HE Xiao-fang,ZHOU Min,XIONG Chao-yue,et al.Ultrasonicsigns of breast cancer and analysis of risk factors for postoperative recurrence[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2022,24(06):274.[doi:10.3969/j.issn.1672-271X.2022.03.011]

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2013-11-20